Genomma Lab Internacional, S.A.B. de C.V.

BMV:LAB B Voorraadrapport

Marktkapitalisatie: Mex$24.9b

Genomma Lab Internacional. de Inkomsten in het verleden

Verleden criteriumcontroles 5/6

Genomma Lab Internacional. de is de winst gegroeid met een gemiddeld jaarlijks percentage van 6.2%, terwijl de Pharmaceuticals industrie de winst jaarlijks groeide met 6.2%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 6.7% per jaar. Het rendement op eigen vermogen van Genomma Lab Internacional. de is 14.4%, en het heeft een nettomarge van 9.2%.

Belangrijke informatie

6.2%

Groei van de winst

7.9%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie12.4%
Inkomstengroei6.7%
Rendement op eigen vermogen14.4%
Nettomarge9.2%
Laatste winstupdate30 Sep 2024

Recente prestatie-updates uit het verleden

Recent updates

Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet

Oct 17
Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet

Calculating The Intrinsic Value Of Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB)

Sep 11
Calculating The Intrinsic Value Of Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB)

With Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) It Looks Like You'll Get What You Pay For

Jul 12
With Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) It Looks Like You'll Get What You Pay For

These 4 Measures Indicate That Genomma Lab Internacional. de (BMV:LABB) Is Using Debt Reasonably Well

May 31
These 4 Measures Indicate That Genomma Lab Internacional. de (BMV:LABB) Is Using Debt Reasonably Well

Here's Why Genomma Lab Internacional. de (BMV:LABB) Can Manage Its Debt Responsibly

Jan 29
Here's Why Genomma Lab Internacional. de (BMV:LABB) Can Manage Its Debt Responsibly

Is Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Trading At A 49% Discount?

Nov 07
Is Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Trading At A 49% Discount?

Is Genomma Lab Internacional. de (BMV:LABB) Using Too Much Debt?

Mar 31
Is Genomma Lab Internacional. de (BMV:LABB) Using Too Much Debt?

Is Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Trading At A 32% Discount?

Feb 24
Is Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Trading At A 32% Discount?

Does Genomma Lab Internacional. de (BMV:LABB) Have A Healthy Balance Sheet?

Dec 07
Does Genomma Lab Internacional. de (BMV:LABB) Have A Healthy Balance Sheet?

Rainbows and Unicorns: Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Analysts Just Became A Lot More Optimistic

Sep 24
Rainbows and Unicorns: Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Analysts Just Became A Lot More Optimistic

Analysts Just Made A Major Revision To Their Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Revenue Forecasts

Aug 01
Analysts Just Made A Major Revision To Their Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Revenue Forecasts

Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet

Jul 27
Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet

Here's Why Genomma Lab Internacional. de (BMV:LABB) Can Manage Its Debt Responsibly

Mar 22
Here's Why Genomma Lab Internacional. de (BMV:LABB) Can Manage Its Debt Responsibly

Are Investors Undervaluing Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) By 44%?

Feb 15
Are Investors Undervaluing Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) By 44%?

Genomma Lab Internacional. de (BMV:LABB) Seems To Use Debt Quite Sensibly

Nov 24
Genomma Lab Internacional. de (BMV:LABB) Seems To Use Debt Quite Sensibly

Here's Why I Think Genomma Lab Internacional. de (BMV:LABB) Is An Interesting Stock

Sep 08
Here's Why I Think Genomma Lab Internacional. de (BMV:LABB) Is An Interesting Stock

Genomma Lab Internacional, S.A.B. de C.V.'s (BMV:LABB) Intrinsic Value Is Potentially 96% Above Its Share Price

Jun 10
Genomma Lab Internacional, S.A.B. de C.V.'s (BMV:LABB) Intrinsic Value Is Potentially 96% Above Its Share Price

Is Genomma Lab Internacional. de (BMV:LABB) A Risky Investment?

May 24
Is Genomma Lab Internacional. de (BMV:LABB) A Risky Investment?

Should You Be Adding Genomma Lab Internacional. de (BMV:LABB) To Your Watchlist Today?

May 06
Should You Be Adding Genomma Lab Internacional. de (BMV:LABB) To Your Watchlist Today?

Investors Who Bought Genomma Lab Internacional. de (BMV:LABB) Shares Five Years Ago Are Now Up 65%

Mar 13
Investors Who Bought Genomma Lab Internacional. de (BMV:LABB) Shares Five Years Ago Are Now Up 65%

Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet

Feb 19
Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet

Do Its Financials Have Any Role To Play In Driving Genomma Lab Internacional, S.A.B. de C.V.'s (BMV:LABB) Stock Up Recently?

Feb 02
Do Its Financials Have Any Role To Play In Driving Genomma Lab Internacional, S.A.B. de C.V.'s (BMV:LABB) Stock Up Recently?

Are Investors Undervaluing Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) By 42%?

Jan 15
Are Investors Undervaluing Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) By 42%?

What Is The Ownership Structure Like For Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB)?

Dec 28
What Is The Ownership Structure Like For Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB)?

Genomma Lab Internacional. de (BMV:LABB) Shareholders Have Enjoyed A 54% Share Price Gain

Dec 10
Genomma Lab Internacional. de (BMV:LABB) Shareholders Have Enjoyed A 54% Share Price Gain

Opbrengsten en kosten

Hoe Genomma Lab Internacional. de geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

BMV:LAB B Opbrengsten, kosten en inkomsten (MXN Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Sep 2417,4661,6037,3030
30 Jun 2416,7671,3137,0700
31 Mar 2416,4861,0456,7200
31 Dec 2316,4671,0856,8380
30 Sep 2317,0741,3926,9880
30 Jun 2317,0301,4217,0020
31 Mar 2316,9831,4086,9320
31 Dec 2216,8201,3896,9220
30 Sep 2216,7781,3597,1850
30 Jun 2216,4121,3537,0430
31 Mar 2215,9541,3286,8770
31 Dec 2115,4871,3086,5700
30 Sep 2114,8681,3526,1350
30 Jun 2114,3121,3685,8720
31 Mar 2114,0831,4165,7360
31 Dec 2013,8701,4045,6660
30 Sep 2013,6191,1795,8990
30 Jun 2013,2681,0035,8240
31 Mar 2012,9108865,8100
31 Dec 1912,7137505,8240
30 Sep 1912,6179355,8150
30 Jun 1912,2749255,7350
31 Mar 1911,9219865,6150
31 Dec 1811,7941,1095,5780
30 Sep 1811,5561,2425,2640
30 Jun 1811,9001,2495,3780
31 Mar 1811,8861,2185,4540
31 Dec 1712,0781,2795,6220
30 Sep 1711,8989586,2950
30 Jun 1711,7411,2126,3830
31 Mar 1711,669-1,6037,5510
31 Dec 1611,316-1,6817,4910
30 Sep 1611,287-3,4478,4380
30 Jun 1610,988-3,7598,3630
31 Mar 1611,125-8957,3250
31 Dec 1511,042-1,1377,3340
30 Sep 1511,2111,1095,7910
30 Jun 1511,9461,4105,8680
31 Mar 1511,8711,3965,7480
31 Dec 1411,5411,4325,5690
30 Sep 1412,3751,7765,5310
30 Jun 1412,0821,7665,4440
31 Mar 1411,7151,7755,2280
31 Dec 1311,3611,7525,0170

Kwaliteitswinsten: LAB B heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: De huidige netto winstmarges (9.2%) LAB B } zijn hoger dan vorig jaar (8.2%).


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: De winst van LAB B is de afgelopen 5 jaar met 6.2% per jaar gegroeid.

Versnelling van de groei: De winstgroei van LAB B over het afgelopen jaar ( 15.1% ) overtreft het 5-jarig gemiddelde ( 6.2% per jaar).

Winst versus industrie: De winstgroei LAB B over het afgelopen jaar ( 15.1% ) overtrof de Pharmaceuticals -sector 8.8%.


Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 14.4% ) van LAB B wordt als laag beschouwd.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden